EGFR and lung cancer: NEtD is a mechanism of acquired resistance to targeted therapy, which predominately occurs in small cell lung cancer (SCLC) and NE prostate cancer (NEPC),1, 2 which transformed from metastatic epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and metastatic castration‐resistant prostate cancer (mCRPC) treated with secondary androgen deprivation therapies (ADTs) (e.g., enzalutamide), respectively.3